title: Comparison of efficacy of pitavastatin and colestimide in Japanese patients with diabetes mellitus complicated by hyperlipidemia and metabolic syndrome.
abstract: The present study was undertaken to compare the efficacy of pitavastatin and colestimide in patients with diabetes mellitus complicated by hyperlipidemia and metabolic syndrome. 48 diabetic patients with metabolic syndrome were randomly assigned to a pitavastatin group or colestimide group. The clinical parameters, serum lipids, fasting (FPG) and postprandial plasma glucose(PPG), HOMA-IR, hemoglobin A1c(HbA1c), hs-CRP and urinary albumin were measured before/after 24-week administration. Treatment with pitavastatin reduced LDL-C and TG, while that with colestimide significantly reduced waist circumference, BMI, LDL-C, HbA1c, FPG, PPG, HOMA-R , hs-CRP and urinary albumin. Percent improvement in LDL-C was greater in the pitavastatin group than in the colestimide group. Colestimide appeared to be useful in the management of Japanese patients with diabetes mellitus complicated by metabolic syndrome, since it alleviates obesity and insulin resistance in addition to exhibiting lipid profile-improving effects, and can thus improve markers of atherosclerosis.
authors.affiliation: Department of Internal Medicine Aichi Koseiren Toyotakousei Hospital, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Kato
authors.forename: K
authors.initials: K
authors.lastname: Inagaki
authors.forename: Y
authors.initials: Y
authors.lastname: Sawai
authors.forename: H
authors.initials: H
authors.lastname: Kanayama
authors.forename: N
authors.initials: N
authors.lastname: Katada
authors.forename: M
authors.initials: M
authors.lastname: Itoh
mesh_terms: D000328:Adult; D000368:Aged; D000419:Albuminuria / Q000517:prevention & control; D050197:Atherosclerosis / Q000517:prevention & control; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000032:analysis; D008078:Cholesterol, LDL / Q000097:blood; D048909:Diabetes Complications / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D004811:Epichlorohydrin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006943:Hyperglycemia / Q000517:prevention & control; D006949:Hyperlipidemias / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D007333:Insulin Resistance; D007564:Japan; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D008875:Middle Aged; D009765:Obesity / Q000150:complications / Q000517:prevention & control; D011804:Quinolines / Q000009:adverse effects / Q000627:therapeutic use*; D012117:Resins, Synthetic / Q000009:adverse effects / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood; D015431:Weight Loss / Q000187:drug effects
chemical_list: D015415:Biomarkers; D002097:C-Reactive Protein; D008078:Cholesterol, LDL; D004811:Epichlorohydrin; D006442:Glycated Hemoglobin; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D007093:Imidazoles; D011804:Quinolines; D012117:Resins, Synthetic; D014280:Triglycerides; C417427:colestimide; C517652:hemoglobin A1c protein, human; C108475:pitavastatin